Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Literature DB >> 20739908

PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Dorit S Berlin¹, Katrin Sangkuhl, Teri E Klein, Russ B Altman.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2011 PMID： 20739908 PMCID： PMC3086341 DOI： 10.1097/FPC.0b013e32833d1011

Source DB: PubMed Journal: Pharmacogenet Genomics ISSN： 1744-6872 Impact factor: 2.089

× No keyword cloud information.

37 in total

1. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke.

Authors: Kristin D Marciante; Rheem A Totah; Susan R Heckbert; Nicholas L Smith; Rozenn N Lemaitre; Thomas Lumley; Kenneth M Rice; Lucia A Hindorff; Joshua C Bis; Brittany Hartman; Bruce M Psaty
Journal: Pharmacogenet Genomics Date: 2008-06 Impact factor: 2.089

2. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo.

Authors: Chen Chen; Guiling Li; Wanmin Liao; Jun Wu; Liu Liu; Ding Ma; Jianfeng Zhou; Reem H Elbekai; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal: J Pharmacol Exp Ther Date: 2009-03-16 Impact factor: 4.030

3. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function.

Authors: Fabien Dutheil; Sandrine Dauchy; Monique Diry; Véronique Sazdovitch; Olivier Cloarec; Lucille Mellottée; Ivan Bièche; Magnus Ingelman-Sundberg; Jean-Pierre Flinois; Isabelle de Waziers; Philippe Beaune; Xavier Declèves; Charles Duyckaerts; Marie-Anne Loriot
Journal: Drug Metab Dispos Date: 2009-04-09 Impact factor: 3.922

4. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors: Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal: Pharmacogenet Genomics Date: 2008-11 Impact factor: 2.089

5. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

Authors: Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert
Journal: Am J Physiol Heart Circ Physiol Date: 2009-05-08 Impact factor: 4.733

6. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.

Authors: S N Batchu; E Law; D R Brocks; J R Falck; J M Seubert
Journal: J Mol Cell Cardiol Date: 2008-10-10 Impact factor: 5.000

7. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines.

Authors: Jian-Gang Jiang; Xiang-Ning Fu; Chun-Lian Chen; Dao-Wen Wang
Journal: Ai Zheng Date: 2009-02-23

8. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo.

Authors: Jessica A Wray; Mary C Sugden; Darryl C Zeldin; Gemma K Greenwood; Salma Samsuddin; Laura Miller-Degraff; J Alyce Bradbury; Mark J Holness; Timothy D Warner; David Bishop-Bailey
Journal: PLoS One Date: 2009-10-12 Impact factor: 3.240

9. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile.

Authors: Jan Börgel; Daniel Bulut; Christoph Hanefeld; Horst Neubauer; Andreas Mügge; Jörg T Epplen; Tim Holland-Letz; Martin Spiecker
Journal: BMC Cardiovasc Disord Date: 2008-12-23 Impact factor: 2.298

10. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population.

Authors: Alexey V Polonikov; Vladimir P Ivanov; Maria A Solodilova; Irina V Khoroshaya; Mikhail A Kozhuhov; Vladimir E Ivakin; Ludmila N Katargina; Ol'ga E Kolesnikova
Journal: Dis Markers Date: 2008 Impact factor: 3.434

5 in total

PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

1. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke.

2. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo.

3. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function.

4. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

5. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

6. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.

7. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines.

8. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo.

9. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile.

10. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population.

Review 1. Bioinformatics and variability in drug response: a protein structural perspective.

2. Genotype and age at Parkinson disease diagnosis.

3. GenDrux: a biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer.

Review 4. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Review 5. The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury.